Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MOR

MorphoSys (MOR)

MorphoSys AG
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MOR
DateTimeSourceHeadlineSymbolCompany
06/20/20242:47AMBusiness WireMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority ShareholdersNASDAQ:MORMorphoSys AG
06/10/202411:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
06/06/20244:36PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
06/05/202410:22AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
06/04/20244:06PMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
06/04/202410:17AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/31/202410:17AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/29/202410:17AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/28/202410:16AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/24/202410:13AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/23/20242:19PMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
05/23/202410:11AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/23/20249:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/21/202410:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/17/202410:15AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/17/202410:15AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/16/20244:43PMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
05/16/202410:11AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/15/202410:09AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/13/202410:19AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
04/29/20244:01PMBusiness WireMorphoSys AG Reports First Quarter 2024 Financial ResultsNASDAQ:MORMorphoSys AG
04/11/20248:39AMBusiness WireMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisNASDAQ:MORMorphoSys AG
03/13/20244:02PMBusiness WireMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
02/06/20246:14AMIH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNASDAQ:MORMorphoSys AG
12/10/20237:31PMBusiness WireMorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 StudyNASDAQ:MORMorphoSys AG
11/20/20235:19PMDow Jones NewsMorphoSys Trial for Blood-Cancer Treatment Reaches Primary EndpointNASDAQ:MORMorphoSys AG
11/20/20234:30PMBusiness WireMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionNASDAQ:MORMorphoSys AG
11/15/20234:01PMBusiness WireMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial ResultsNASDAQ:MORMorphoSys AG
08/09/20234:01PMBusiness WireMorphoSys AG Reports Second Quarter and First Half 2023 Financial ResultsNASDAQ:MORMorphoSys AG
05/03/20234:01PMBusiness WireMorphoSys AG Reports First Quarter 2023 Financial ResultsNASDAQ:MORMorphoSys AG
 Showing the most relevant articles for your search:NASDAQ:MOR